Xeomin® (incobotulinumtoxinA) is the latest contender in a growing list of botulinum toxin type A injectables. The Food and Drug Administration (FDA) approved Xeomin® in July 2011 for the treatment of severe frown lines or “11’s” between the eyes. This Botox® alternative was already approved for use in adults with cervical dystonia and blepharospasm. Cervical dystonia is characterized by abnormal neck pain and movements, and blepharospasm is marked by abnormal, involuntary blinking or spasm of the eyelids. Xeomin® is manufactured by Merz Pharmaceuticals.
With the new cosmetic approval, Xeomin® now joins the ranks of Botox® and Dysport®. Other Botox® alternatives, including a topical form of Botox®, are currently being studied as well. Worldwide, more than 84,000 people have been treated with Xeomin® injections. The U.S. is actually the 20th country to approve this new drug. It will be available in 50-unit and 100-unit vials.